INDICATIONS
• Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

• Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

DOSAGE AND ADMINISTRATION
Recommended Dosage for patients with Chronic Liver Disease

• Begin Avatrombopag dosing 10-13 days prior to the scheduled procedure. Patients should undergo their procedure 5 to 8 days after the last dose of Avatrombopag.

• Avatrombopag should be taken orally once daily for 5 consecutive days with food.

• The recommended daily dose of Avatrombopag is based on the patient’s platelet count prior to the scheduled procedure (Refer to Table 1).

• In the case of a missed dose, patients should take the next dose of Avatrombopag as soon as they remember. Patients should not take two doses at one time to make up for a missed dose and should take the next dose at the usual time the next day; all five days of dosing should be completed.

Table 1: Recommended Dose and Duration

Recommended Dosage for Patients with Chronic Immune Thrombocytopenia

• Use the lowest dose of Avatrombopag needed to achieve and maintain a platelet count greater than or equal to 50 x109 /L as necessary to reduce the risk for bleeding.

• Dose adjustments are based on platelet count response.

• Do not use Avatrombopag to normalize platelet counts.

Initial Dose Regimen:
Begin Avatrombopag at a starting dose of 20 mg (1 tablet) once daily with food.

Discontinuation: 
Discontinue Avatrombopag if the platelet count does not increase to greater than or equal to 50 x109 /L after 4 weeks of dosing at the maximum dose of 40 mg once daily. Discontinue Avatrombopag if the platelet count is greater than 400 x109 /L after 2 weeks of dosing at 20 mg once weekly.

FIND A PRODUCT